Drugs, Drugs and More Drugs | Get ready for a no-nonsense tour-de-force of practical application in the latest derm literature. Pipeline drugs, new approvals, brand names, generics—and HS data you’re better off ignoring (we’ll tell you why). In this episode:· Leqselvi: the newest JAK for alopecia areata—actually different, or more of the same?· HS & spondyloarthritis: are you screening… should you be?· JAKs and the heart: are all cardiovascular risks created equal?· “2/3 HS remission” headlines: why this data shouldn’t change your practice· Tirbanibulin + cryo for AKs: combo win or marketing math?· Hydrochlorothiazide & skin cancer: do you really need that conversation?· Oral minoxidil + Olumiant: synergy or wishful thinking in AA?· OX40/OX40L blockers: exciting pathway—new hope or new hype? Fast. Practical. Slightly skeptical (for good reason).If you prescribe, counsel, or roll your eyes at bad data—this one’s for you.